Modulating Myofibroblast Activity via Fibromodulin and TGF-β1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for treating or ameliorating conditions associated with excessive or deficient myofibroblast activities, which are linked to various diseases.
Innovation Solution
Modulating myofibroblast activity by adjusting fibromodulin levels in subjects, either by increasing or decreasing fibromodulin levels using genetic engineering, protein administration, or blocking fibromodulin activity with anti-sense oligonucleotides and peptides, in combination with TGF-β1 to promote differentiation and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is applied, then myofibroblast activity remains uncontrolled, but conditions associated with excessive or deficient myofibroblast activities progress without effective intervention
Solution Approach 1:
The patent modulates myofibroblast activity by changing the concentration and timing of TGF-β1 application, transitioning from no treatment to controlled treatment with specific dosage regimens. This parameter change enables effective treatment of conditions associated with excessive or deficient myofibroblast activities.
Solution Approach 2:
TGF-β1 serves as an intermediary substance that mediates the modulation of myofibroblast activity. By introducing this intermediate agent, the patent enables control over myofibroblast functions without directly manipulating the myofibroblasts themselves, providing a versatile treatment mechanism for multiple conditions.
2Productivity
If myofibroblast activity is increased to promote tissue repair, then early wound healing is improved, but prolonged myofibroblast activity leads to fibrosis and scarring
Solution Approach 1:
The patent employs periodic action by applying TGF-β1 in a time-dependent manner - high concentration during early wound healing phase to stimulate myofibroblast activity and promote rapid tissue repair, then reducing or withdrawing the stimulus to allow myofibroblast activity to decline naturally, preventing prolonged activity that would lead to fibrosis and scarring.
Solution Approach 2:
The treatment approach is dynamic, adjusting TGF-β1 concentration and application timing based on the wound healing stage. This dynamic modulation enables the system to promote myofibroblast activity when needed for tissue repair while automatically limiting duration to prevent pathological fibrosis, thereby resolving the contradiction between healing rate and activity duration.
Data Source
AI summary
The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.